208 related articles for article (PubMed ID: 31142846)
21. Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.
Malato A; Rossi E; Palumbo GA; Guglielmelli P; Pugliese N
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486130
[TBL] [Abstract][Full Text] [Related]
22. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
Björkholm M; Derolf AR; Hultcrantz M; Kristinsson SY; Ekstrand C; Goldin LR; Andreasson B; Birgegård G; Linder O; Malm C; Markevärn B; Nilsson L; Samuelsson J; Granath F; Landgren O
J Clin Oncol; 2011 Jun; 29(17):2410-5. PubMed ID: 21537037
[TBL] [Abstract][Full Text] [Related]
23. Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
Björkholm M; Hultcrantz M; Derolf ÅR
Best Pract Res Clin Haematol; 2014 Jun; 27(2):141-53. PubMed ID: 25189725
[TBL] [Abstract][Full Text] [Related]
24. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
Tefferi A; Szuber N; Vallapureddy RR; Begna KH; Patnaik MM; Elliott MA; Christopher Hook C; Wolanskyj AP; Hanson CA; Ketterling RP; Pardanani A; Gangat N
Am J Hematol; 2019 Jan; 94(1):5-9. PubMed ID: 30252953
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
Choi HS; Hong J; Hwang SM; Lee JH; Ma Y; Kim SA; Lee JY; Lee JO; Bang SM
Ann Hematol; 2021 Oct; 100(10):2567-2574. PubMed ID: 34331110
[TBL] [Abstract][Full Text] [Related]
26. Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
Radaelli F; Onida F; Rossi FG; Zilioli VR; Colombi M; Usardi P; Calori R; Zanella A
Hematology; 2008 Aug; 13(4):195-202. PubMed ID: 18796244
[TBL] [Abstract][Full Text] [Related]
27. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
[TBL] [Abstract][Full Text] [Related]
28. Minimal residual disease or cure in MPNs? Rationales and perspectives on combination therapy with interferon-alpha2 and ruxolitinib.
Bjørn ME; Hasselbalch HC
Expert Rev Hematol; 2017 May; 10(5):393-404. PubMed ID: 28402197
[TBL] [Abstract][Full Text] [Related]
29. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
Stein BL; Gotlib J; Arcasoy M; Nguyen MH; Shah N; Moliterno A; Jamieson C; Pollyea DA; Scott B; Wadleigh M; Levine R; Komrokji R; Klisovic R; Gundabolu K; Kropf P; Wetzler M; Oh ST; Ribeiro R; Paschal R; Mohan S; Podoltsev N; Prchal J; Talpaz M; Snyder D; Verstovsek S; Mesa RA
J Natl Compr Canc Netw; 2015 Apr; 13(4):424-34. PubMed ID: 25870379
[TBL] [Abstract][Full Text] [Related]
30. Treatment of polycythaemia vera and essential thrombocythaemia.
Tefferi A; Silverstein MN
Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
[TBL] [Abstract][Full Text] [Related]
31. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
32. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
33. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.
Mora B; Rumi E; Guglielmelli P; Barraco D; Maffioli M; Rambaldi A; Caramella M; Komrokji R; Gotlib J; Kiladjian JJ; Cervantes F; Devos T; Palandri F; De Stefano V; Ruggeri M; Silver RT; Benevolo G; Albano F; Cavalloni C; Pietra D; Barbui T; Rotunno G; Cazzola M; Vannucchi AM; Giorgino T; Passamonti F
Cancer Med; 2019 Aug; 8(9):4089-4092. PubMed ID: 31173472
[TBL] [Abstract][Full Text] [Related]
34. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
[TBL] [Abstract][Full Text] [Related]
35. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.
Silver RT; Kiladjian JJ; Hasselbalch HC
Expert Rev Hematol; 2013 Feb; 6(1):49-58. PubMed ID: 23373780
[TBL] [Abstract][Full Text] [Related]
36. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A
Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522
[TBL] [Abstract][Full Text] [Related]
37. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
Panova-Noeva M; Marchetti M; Buoro S; Russo L; Leuzzi A; Finazzi G; Rambaldi A; Ottomano C; Ten Cate H; Falanga A
Blood; 2011 Sep; 118(9):2599-601. PubMed ID: 21750318
[TBL] [Abstract][Full Text] [Related]
38. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
39. The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
Griesshammer M; Sadjadian P
Expert Opin Pharmacother; 2017 Dec; 18(18):1929-1938. PubMed ID: 29134817
[TBL] [Abstract][Full Text] [Related]
40. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Randi ML; Fabris F; Girolami A
Leuk Lymphoma; 2000 Apr; 37(3-4):379-85. PubMed ID: 10752989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
